

V. Balasubramanian

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 09	JAPIO to be reloaded August 18, 2002
NEWS EXPRESS			February 1 CURRENT WINDOWS VERSION IS V6.0d, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:32:29 ON 09 AUG 2002

10/069,019

V. Balasubramanian

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 15:32:40 ON 09 AUG 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 AUG 2002 HIGHEST RN 443281-25-2

DICTIONARY FILE UPDATES: 8 AUG 2002 HIGHEST RN 443281-25-2

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>

Uploading C:\STNEXP4\QUERIES\10069019.str

L1 STRUCTURE UPLOADED


=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 [01],[02]

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:33:03 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 15 TO ITERATE

100.0% PROCESSED 15 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 68 TO 532

PROJECTED ANSWERS: 6 TO 266


L3 6 SEA SSS SAM L1

=> d scan

L3 6 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-
[(dimethylamino)methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)

MF C30 H36 F N7




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):5

L3 6 ANSWERS REGISTRY COPYRIGHT 2002 ACS

IN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-
(9CI)

MF C17 H14 N6 O2 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 6 ANSWERS REGISTRY COPYRIGHT 2002 ACS


IN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-
N-(3-methoxypropyl)- (9CI)

MF C21 H22 N6 O3 S




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 6 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-
N-[2-(1H-imidazol-4-yl)ethyl]- (9CI)
MF C22 H20 N8 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L3 6 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Benzenesulfonamide, N-[2-(diethylamino)ethyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI)
MF C23 H27 N7 O2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L3 6 ANSWERS REGISTRY COPYRIGHT 2002 ACS
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)
MF C28 H31 F N6

V. Balasubramanian



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful
FULL SEARCH INITIATED 15:33:45 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 251 TO ITERATE

100.0% PROCESSED 251 ITERATIONS 152 ANSWERS
SEARCH TIME: 00.00.02

L4 152 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	141.04	141.25

FILE 'CAPLUS' ENTERED AT 15:34:16 ON 09 AUG 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Aug 2002 VOL 137 ISS 7
FILE LAST UPDATED: 8 Aug 2002 (20020808/ED)

10/069,019

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 14

L5 4 L4

=> d 15 1-4 bib hitstr

L5 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2002 ACS

AN 2002:466008 CAPLUS

DN 137:33325

TI Preparation of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents

IN Boyd, F. Leslie; Chamberlain, Stanley D.; Cheung, Mui; Gudmundsson, Kristjan; Harris, Philip Anthony; Johns, Brian A.; Jung, David Kendall; Peel, Michael Robert; Stanford, Jennifer Badiang; Sexton, Connie Jo

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 159 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002048148	A2	20020620	WO 2001-US44231	20011126
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-255763P	P	20001215		
	US 2001-274284P	P	20010308		
OS	MARPAT 137:33325				
IT	437612-03-8P 437612-12-9P 437612-13-0P 437612-20-9P 437612-22-1P 437612-23-2P 437612-46-9P 437612-48-1P 437612-70-9P				
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(prepn. of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)				
RN	437612-03-8 CAPLUS				
CN	2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-methyl- (9CI) (CA INDEX NAME)				

V. Balasubramanian



RN 437612-12-9 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-
[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)



RN 437612-13-0 CAPLUS


CN 4-Pyrimidinemethanol, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-
3-yl]-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437612-20-9 CAPLUS

CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 437612-22-1 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 437612-23-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-


V. Balasubramanian

a]pyridin-3-yl]-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




RN 437612-46-9 CAPLUS

CN 4-Pyrimidinemethanamine, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 437612-48-1 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl- (9CI) (CA INDEX NAME)




RN 437612-70-9 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-5-methyl- (9CI) (CA INDEX NAME)

V. Balasubramanian

a]pyridin-3-yl]-N-cyclopentyl-2-(cyclopentylamino)- (9CI) (CA INDEX NAME)




IT 437611-97-7P 437612-00-5P 437612-02-7P
437612-04-9P 437612-06-1P 437612-10-7P
437612-11-8P 437612-15-2P 437612-16-3P
437612-17-4P 437612-18-5P 437612-19-6P
437612-21-0P 437612-27-6P 437612-47-0P
437612-49-2P 437612-67-4P 437612-68-5P
437612-71-0P 437612-75-4P 437612-76-5P
437612-78-7P 437613-20-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine
derivs. as antiviral agents)

RN 437611-97-7 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-
pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-00-5 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopropylamino)-4-
pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437612-02-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-04-9 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-06-1 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437612-10-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-hydrazinopyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



RN 437612-11-8 CAPLUS


CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-methyl- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 437612-15-2 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(4-methyl-1-piperazinyl)pyrazolo[1,5-a]pyridin-3-yl]-6-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 437612-16-3 CAPLUS


CN 1,2-Ethanediamine, N-[3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)



RN 437612-17-4 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437612-18-5 CAPLUS

CN 4-Pyrimidinemethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 437612-19-6 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 437612-21-0 CAPLUS

CN Glycine, N-[3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-


V. Balasubramanian

fluorophenyl)pyrazolo[1,5-a]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 437612-27-6 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(4-fluorophenyl)-7-(1-pyrrolidin-2-yl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 437612-47-0 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-[(dimethylamino)methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 437612-49-2 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-5-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-67-4 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclohexyl-3-[2-(cyclohexylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437612-68-5 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 437612-71-0 CAPLUS


CN 4-Pyrimidinecarboxamide, N-cyclopentyl-2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)
(CA INDEX NAME)



RN 437612-75-4 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopropyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437612-76-5 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437612-78-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-phenyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 437613-20-2 CAPLUS

CN 4-Pyrimidinemethanol, 2-(cyclopentylamino)-6-[7-(cyclopentylamino)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

IT 437612-94-7P 437612-97-0P 437613-09-7P


437613-12-2P 437613-19-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyrazolopyridinylpyrimidine and pyrazolopyridinylpyridine derivs. as antiviral agents)

RN 437612-94-7 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-[(tetrahydro-2H-pyran-2-yl)oxy]methyl- (9CI) (CA INDEX NAME)



RN 437612-97-0 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437613-09-7 CAPLUS

CN 2-Pyrimidinamine, 4-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-6-(iodomethyl)- (9CI) (CA INDEX NAME)



RN 437613-12-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[7-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-(cyclopentylamino)-, methyl ester (9CI) (CA INDEX NAME)




RN 437613-19-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-bromo-4-chlorophenyl)-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002048147	A2	20020620	WO 2001-US44210	20011126
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW:			
		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-255763P	P	20001215		
	US 2001-274284P	P	20010308		
	US 2001-315089P	P	20010827		
OS	MARPAT 137:33316				
IT	437384-04-8P	437384-11-7P	437384-12-8P		
	437384-13-9P	437384-14-0P	437384-23-1P		
	437384-32-2P	437384-33-3P			
	RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				
	(prepn. of pyrazolopyridinamine derivs. as antiviral agents)				
RN	437384-04-8	CAPLUS			
CN	Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)				

V. Balasubramanian




RN 437384-11-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(3,4,5-trimethoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 437384-12-8 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-methoxyphenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 437384-13-9 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-[(4-fluorophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 437384-14-0 CAPLUS

CN Methanone, [3-[[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 437384-23-1 CAPLUS


CN 2-Pyrimidinamine, 4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 437384-32-2 CAPLUS


CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-2-(4-methoxyphenyl)-3-[2-[(3-nitrophenyl)amino]-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 437384-33-3 CAPLUS

CN Benzenemethanol, 3-[[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI)
(CA INDEX NAME)



IT 437384-29-7P 437384-30-0P 437384-31-1P


437384-36-6P 437384-37-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazolopyridinamine derivs. as antiviral agents)

RN 437384-29-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-5-amine, N-cyclopentyl-2-(4-fluorophenyl)-3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-30-0 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-2-(4-fluorophenyl)-


V. Balasubramanian

3-[2-(phenylamino)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 437384-31-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-chloro-7-(ethylthio)-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 437384-36-6 CAPLUS

CN 1,3-Benzenediamine, N-[4-[7-(cyclopentylamino)-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)



RN 437384-37-7 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-[(3-azidophenyl)amino]-4-pyrimidinyl]-N-cyclopentyl-2-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2002 ACS

AN 2002:157771 CAPLUS

DN 136:200184

TI Preparation of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases

IN Alberti, Michael John; Baldwin, Ian Robert; Cheung, Mui; Cockerill, Stuart; Flack, Stephen; Harris, Philip Anthony; Jung, David Kendall; Peckham, Gregory; Peel, Michael Robert; Stanford, Jennifer Badiang; Stevens, Kirk; Veal, James Marvin

PA Glaxo Group Limited, UK

SO PCT Int. Appl., 173 pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016359	A1	20020228	WO 2001-GB3783	20010822
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001082318	A5	20020304	AU 2001-82318	20010822
PRAI	GB 2000-20556	A	20000822		
	GB 2000-20576	A	20000822		
	WO 2001-GB3783	W	20010822		
OS	MARPAT 136:200184				
IT	401816-50-0P , N-Cyclopropyl-4-[2-(4-fluorophenyl)-6-trifluoromethylpyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (protein kinase inhibitor; prepn. of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)				
RN	401816-50-0 CAPLUS				
CN	2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)				



IT **401816-38-4P**, N-Cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine **401816-57-7P**, N-Cyclopropyl-4-[6-cyano-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine **401816-61-3P**, 2-(4-Fluorophenyl)-3-[2-(cyclopropylamino)-4-pyrimidinyl]-6-pyrazolo[1,5-a]pyridinylcarboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protein kinase inhibitor; prepn. of pyrazolo[1,5-a]pyridines as protein kinase inhibitors for treatment of inflammatory and autoimmune diseases)
 RN 401816-38-4 CAPLUS
 CN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 401816-57-7 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carbonitrile, 3-[2-(cyclopropylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 401816-61-3 CAPLUS
 CN Pyrazolo[1,5-a]pyridine-6-carboxamide, 3-[2-(cyclopropylamino)-4-

V. Balasubramanian

pyrimidinyl]-2-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2002 ACS

AN 2001:152681 CAPLUS

DN 134:193444

TI Preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases.

IN Thomas, Andrew Peter; Breault, Gloria Anne; Beattie, John Franklin; Jewsbury, Phillip John

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001014375	A1	20010301	WO 2000-GB3139	20000815
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000013476	A	20020430	BR 2000-13476	20000815
	EP 1214318	A1	20020619	EP 2000-953319	20000815
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NO 2002000832	A	20020412	NO 2002-832	20020220
PRAI	GB 1999-19778	A	19990821		
	WO 2000-GB3139	W	20000815		
OS	MARPAT 134:193444				
IT	328061-31-0P 328061-32-1P 328061-33-2P 328061-34-3P 328061-35-4P 328061-36-5P 328061-37-6P 328061-38-7P 328061-39-8P 328061-40-1P 328061-41-2P 328061-42-3P 328061-43-4P 328061-44-5P 328061-45-6P 328061-46-7P 328061-47-8P 328061-48-9P 328061-49-0P 328061-50-3P 328061-51-4P				


328061-52-5P 328061-53-6P 328061-54-7P
 328061-55-8P 328061-56-9P 328061-57-0P
 328061-58-1P 328061-59-2P 328061-60-5P
 328061-61-6P 328061-62-7P 328061-63-8P
 328061-64-9P 328061-65-0P 328061-66-1P
 328061-67-2P 328061-68-3P 328061-69-4P
 328061-70-7P 328061-71-8P 328061-72-9P
 328061-73-0P 328061-74-1P 328061-75-2P
 328061-76-3P 328061-77-4P 328061-78-5P
 328061-79-6P 328061-80-9P 328061-81-0P
 328061-82-1P 328061-83-2P 328061-84-3P
 328061-85-4P 328061-86-5P 328061-87-6P
 328061-88-7P 328061-89-8P 328061-90-1P
 328061-91-2P 328061-92-3P 328061-93-4P
 328061-94-5P 328061-95-6P 328061-96-7P
 328061-97-8P 328061-98-9P 328061-99-0P
 328062-00-6P 328062-01-7P 328062-02-8P
 328062-03-9P 328062-04-0P 328062-05-1P
 328062-06-2P 328062-07-3P 328062-08-4P
 328062-09-5P 328062-10-8P 328062-11-9P
 328062-12-0P 328062-13-1P 328062-14-2P
 328062-15-3P 328062-16-4P 328062-17-5P
 328062-18-6P 328062-19-7P 328062-20-0P
 328062-21-1P 328062-22-2P 328062-23-3P
 328062-24-4P 328062-25-5P 328062-26-6P
 328062-27-7P 328064-26-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases)


RN 328061-31-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



RN 328061-32-1 CAPLUS


CN Benzenesulfonamide, 4-[[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 328061-33-2 CAPLUS


V. Balasubramanian

CN 2-Pyrimidinamine, 4-(2-methylimidazo[1,2-a]pyridin-3-yl)-N-phenyl- (9CI)
(CA INDEX NAME)




RN 328061-34-3 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(2-methylimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 328061-35-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI)
(CA INDEX NAME)



RN 328061-36-5 CAPLUS


CN 2-Pyrimidinamine, N-(3,4-dichlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 328061-37-6 CAPLUS


CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328061-38-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-4-fluorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 328061-39-8 CAPLUS

CN 2-Pyrimidinamine, N-(2-chlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 328061-40-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-chloro-4-methylphenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 328061-41-2 CAPLUS


CN 4H-1,3,5-Dioxazine, dihydro-5-[[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 328061-42-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 328061-43-4 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 328061-44-5 CAPLUS

CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 328061-45-6 CAPLUS


CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 328061-46-7 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-phenyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328061-47-8 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI)
(CA INDEX NAME)




RN 328061-48-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-bromophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI)
(CA INDEX NAME)




RN 328061-49-0 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI)
(CA INDEX NAME)



RN 328061-50-3 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(3-methoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 328061-51-4 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[3-(methylthio)phenyl]-
(9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328061-52-5 CAPLUS

CN Ethanone, 1-[3-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 328061-53-6 CAPLUS

CN 2-Pyrimidinamine, N-(3-ethylphenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 328061-54-7 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 328061-55-8 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 328061-56-9 CAPLUS


CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328061-57-0 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-phenyl- (9CI) (CA INDEX NAME)




RN 328061-58-1 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 328061-59-2 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 328061-60-5 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 328061-61-6 CAPLUS

CN Benzenesulfonamide, 3-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-62-7 CAPLUS

CN Benzenesulfonamide, 3-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-2-pyrimidinyl- (9CI) (CA INDEX NAME)




RN 328061-63-8 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 328061-64-9 CAPLUS

CN 2-Pyrimidinamine, 4-imidazo[1,2-a]pyridin-3-yl-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 328061-65-0 CAPLUS

CN 2-Pyrimidinamine, N-(2,3-dihydro-1H-inden-5-yl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI) (CA INDEX NAME)




RN 328061-66-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2,5-dimethylimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 328061-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




RN 328061-68-3 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 328061-69-4 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328061-70-7 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 328061-71-8 CAPLUS

CN Benzenesulfonamide, N-cyclopropyl-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-72-9 CAPLUS

CN Benzamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 328061-73-0 CAPLUS

CN Benzamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-methyl- (9CI) (CA INDEX NAME)




RN 328061-74-1 CAPLUS

CN Benzenesulfonamide, N-(3-hydroxypropyl)-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-75-2 CAPLUS

CN Benzenesulfonamide, N-(cyclopropylmethyl)-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-76-3 CAPLUS

CN Benzenesulfonamide, N-(5-hydroxypentyl)-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-77-4 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 328061-78-5 CAPLUS

CN Benzenesulfonamide, N-[3-(diethylamino)propyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-79-6 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-[(1-methylethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 328061-80-9 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 328061-81-0 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-(3-methoxypropyl)- (9CI) (CA INDEX NAME)




RN 328061-82-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-[(1-methylethyl)amino]propyl]- (9CI) (CA INDEX NAME)




RN 328061-83-2 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 328061-84-3 CAPLUS

CN Benzenesulfonamide, N-[3-(dimethylamino)propyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-85-4 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)




RN 328061-86-5 CAPLUS

CN Benzenesulfonamide, N-(3-aminopropyl)-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-87-6 CAPLUS

CN Benzenesulfonamide, N-[2-[(2-hydroxyethyl)amino]ethyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-88-7 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 328061-89-8 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(methylamino)propyl]- (9CI) (CA INDEX NAME)




RN 328061-90-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 328061-91-2 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)




RN 328061-92-3 CAPLUS

CN Benzenesulfonamide, N-[2-[[2-(diethylamino)ethyl]amino]ethyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-93-4 CAPLUS

CN Benzenesulfonamide, N-(2,3-dihydroxypropyl)-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-94-5 CAPLUS

CN Benzenesulfonamide, N-[2-(dimethylamino)ethyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)




RN 328061-95-6 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 328061-96-7 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 328061-97-8 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 328061-98-9 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 328061-99-0 CAPLUS


CN Benzenesulfonamide, N-[2-(diethylamino)ethyl]-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]- (9CI) (CA INDEX NAME)



V. Balasubramanian


RN 328062-00-6 CAPLUS

CN Benzamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)




RN 328062-01-7 CAPLUS

CN Benzamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 328062-02-8 CAPLUS

CN Benzenesulfonamide, 2-chloro-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328062-03-9 CAPLUS

CN Benzenesulfonamide, 2-chloro-4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 328062-04-0 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 328062-05-1 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 328062-06-2 CAPLUS

CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-2-methyl-N-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 328062-07-3 CAPLUS


CN Benzenesulfonamide, 4-[(4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-2-methyl-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 328062-08-4 CAPLUS


CN Benzenesulfonamide, 4-[(5-bromo-4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl)amino]-2-methyl- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328062-09-5 CAPLUS

CN Benzenesulfonamide, 4-[(5-bromo-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328062-10-8 CAPLUS

CN Benzenesulfonamide, 4-[(5-bromo-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 328062-11-9 CAPLUS

CN Benzenesulfonamide, 4-[(5-bromo-4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)




RN 328062-12-0 CAPLUS

CN Benzenesulfonamide, 4-[[4-(5-bromoimidazo[1,2-a]pyridin-3-yl)-2-


V. Balasubramanian

pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328062-13-1 CAPLUS

CN Benzenesulfonamide, N-(2-methoxyethyl)-4-[[4-[5-(phenylthio)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 328062-14-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-[5-(ethylthio)imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328062-15-3 CAPLUS

CN Benzenesulfonamide, 4-[[4-[5-[(2-hydroxyethyl)thio]imidazo[1,2-a]pyridin-3-yl]-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




V. Balasubramanian




RN 328062-20-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(2-hydroxyethyl)thio]-4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328062-21-1 CAPLUS

CN Carbamic acid, [3-[[[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 328062-22-2 CAPLUS


CN Carbamic acid, [3-[[[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]propyl]-, phenylmethylester (9CI) (CA INDEX NAME)



RN 328062-23-3 CAPLUS


CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-(6-phenylimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328062-20-0 CAPLUS

CN Benzenesulfonamide, 4-[[5-[(2-hydroxyethyl)thio]-4-imidazo[1,2-a]pyridin-3-yl-2-pyrimidinyl]amino]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 328062-21-1 CAPLUS

CN Carbamic acid, [3-[[[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 328062-22-2 CAPLUS


CN Carbamic acid, [3-[[[4-[(4-imidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenyl]sulfonyl]amino]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 328062-23-3 CAPLUS


CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-(6-phenylimidazo[1,2-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)

V. Balasubramanian




RN 328062-24-4 CAPLUS

CN Benzenesulfonamide, 4-[[4-(6-methoxy-2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 328062-25-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-pyrazolo[1,5-a]pyridin-3-yl- (9CI) (CA INDEX NAME)



RN 328062-26-6 CAPLUS


CN 2-Pyrimidinamine, 5-bromo-4-imidazo[1,2-a]pyridin-3-yl-N-phenyl- (9CI) (CA INDEX NAME)



RN 328062-27-7 CAPLUS


CN 2-Pyrimidinamine, 4-(5-bromoimidazo[1,2-a]pyridin-3-yl)-N-phenyl- (9CI) (CA INDEX NAME)

V. Balasubramanian



RN 328064-26-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-imidazo[1,2-a]pyridin-3-yl- (9CI)
(CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.62

153.87

STN INTERNATIONAL LOGOFF AT 15:34:55 ON 09 AUG 2002